World's Best Scientists 2026 revealed!
Award Badge
Medicine
Ireland
2023

D-Index & Metrics

Medicine

D-Index
144
Citations
76008
World Ranking
1447
National Ranking
845

Research.com Recognitions

  • 2023 - Research.com Medicine in Ireland Leader Award
  • 2022 - Research.com Medicine in Ireland Leader Award

Overview

Francis J. Giles is affiliated with Northwestern University in the United States. Their research spans multiple areas primarily within the fields of Medicine and Biochemistry, Genetics and Molecular Biology. The scientist's work has a strong focus on molecular biology, oncology, hematology, genetics, and pathology and forensic medicine.

The scientist has contributed extensively to topics such as Wnt/β-catenin signaling in development and cancer, cancer-related gene regulation, protein degradation and inhibitors, chronic lymphocytic leukemia research, chronic myeloid leukemia treatments, cancer immunotherapy and biomarkers, and ubiquitin and proteasome pathways.

Frequent publication venues include:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Molecular Cancer Therapeutics
  • Leukemia

Notable recent papers authored or coauthored by Francis J. Giles include:

  • A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors (2020), Clinical Cancer Research
  • A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma (2021), Science Translational Medicine
  • Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer (2020), Nature Communications
  • Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734 (2020), Molecular Cancer Therapeutics
  • Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial (2021), Journal of Hematology & Oncology

Frequent coauthors collaborating with Francis J. Giles include Benedito A. Carneiro, Ludimila Cavalcante, Howard Safran, Steven Powell, and Andrew P. Mazar.

Best Publications

  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

    Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

    Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

    Hagop M Kantarjian;Susan O'Brien;Terry L. Smith;Jorge E Cortes

  • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

    B. Douglas Smith;Mark Levis;Mark Levis;Miloslav Beran;Miloslav Beran;Francis Giles;Francis Giles

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

    Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes

  • Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop Kantarjian;Deborah A. Thomas;Francis J. Giles

  • Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

    Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance

    Jennifer S. Carew;Steffan T. Nawrocki;Charissa N. Kahue;Hui Zhang

  • Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

    Thomas Fischer;Richard M. Stone;Daniel J. DeAngelo;Ilene Galinsky

  • Wnt/beta-catenin pathway: modulating anticancer immune response.

    Sachin Gopalkrishna Pai;Sachin Gopalkrishna Pai;Benedito A. Carneiro;Jose Mauricio Mota;Ricardo Costa

  • Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

    Jennifer S. Carew;Francis J. Giles;Steffan T. Nawrocki

  • High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia

    Hagop Kantarjian;Moshe Talpaz;Susan O'Brien;Guillermo Garcia-Manero

  • Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

    Andres O. Soriano;Hui Yang;Stefan Faderl;Zeev Estrov

  • Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

    Alvaro Aguayo;Elihu Estey;Elihu Estey;Hagop M Kantarjian;Hagop M Kantarjian;Taghi Mansouri;Taghi Mansouri

  • Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop M. Kantarjian;Jorge Cortes;Miloslav Beran

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Susan O'Brien
Susan O'Brien University of California, Irvine
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Deborah A. Thomas
Deborah A. Thomas The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Elihu H. Estey
Elihu H. Estey University of Washington
Maher Albitar
Maher Albitar Genomic Testing Cooperative

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring the field of medicine in the USA doesn't always mean traditional medical school. There are a variety of online programs that open doors to fulfilling careers in healthcare, offering greater flexibility and affordability.

Many students start their healthcare journey by taking billing and coding classes online. These courses offer a fast track into the administrative side of healthcare, with strong job growth and the option to work remotely.

For those interested in patient care, enrolling in an online nursing school can lead to an in-demand nursing career while offering substantial schedule flexibility for busy adults. If you wish to pursue advanced practice, there are also many cheapest nurse practitioner programs available online. These programs prepare graduates for expanded clinical roles in a variety of healthcare settings.

For nursing professionals seeking leadership or research roles, online PhD programs in nursing allow students to earn the highest credential in nursing from home. Each of these options offers pathways to rewarding careers and can be a stepping stone to further studies in medicine or healthcare.

Best Scientists Citing Francis J. Giles

Trending Scientists

Recently Published Articles